| Trial ID: | L0382 |
| Source ID: | JPRN-jRCT2051210037
|
| Associated Drug: |
BI 456906
|
| Title: |
Multicenter, double-blind, parallel-group, randomised, 48 weeks, dose-ranging, placebo-controlled phase II trial to evaluate efficacy, safety and tolerability of multiple subcutaneous (s.c.) doses of BI 456906 in patients with non-alcoholic steatohepatiti
|
| Acronym: |
--
|
| Status: |
Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Non-alcoholic steatohepatitis
|
| Interventions: |
Investigational Medical Product: BI 456906 or Placebo
|
| Outcome Measures: |
The improvement (yes/ no) from baseline in liver histological findings based on liver biopsy after 48 weeks of treatment in patients with NASH (NAS >= 4, fibrosis F1-F3).nan
|
| Sponsor/Collaborators: |
Kenmochi Hiroki
|
| Gender: |
All
|
| Age: |
>= 20age old<= 80age old
|
| Phases: |
Phase 2
|
| Enrollment: |
240
|
| Study Type: |
Interventional
|
| Study Designs: |
randomized controlled trial, double blind, placebo control, parallel assignment, treatment purpose
|
| Start Date: |
14/06/2021
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
10 January 2022
|
| Locations: |
Australia;Austria;Belgium;Canada;China;Czech Republic;Germany;Spain;France;United Kingdom;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Netherlands;New Zealand;Poland;Singapore;Taiwan;United States;Japan
|
| URL: |
https://jrct.niph.go.jp/latest-detail/jRCT2051210037
|
